---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002526"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:57:00.640680+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX reports Q4 rev $19.7M, cash $305.2M; CX-2029 18.8% ORR, CX-904 IND allowed

## Summary
- Cash and equivalents $305.2M at Dec 31, 2021 vs $316.1M at Dec 31, 2020.
- Q4 2021 revenue $19.7M (up from $16.4M in Q4 2020); FY 2021 revenue $69.6M (down from $100.4M).
- CX-2029 Phase 2 in sqNSCLC: 18.8% objective response rate, 87.5% disease control rate; safety consistent.
- CX-904 (EGFRxCD3 TCB) IND allowed; Phase 1 in advanced solid tumors to start H1 2022.
- Praluzatamab ravtansine Phase 2 in breast cancer: initial data for Arms A & B expected H2 2022.

## SEC filing metadata
- accession: 0000950170-22-002526
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017022002526/0000950170-22-002526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017022002526/ctmx-20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002526
- JSON: https://secwatch.observer/filing/0000950170-22-002526.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.